Muscarinic acetylcholine receptors (mAChRs) are central to the modulation of neurotransmission in the human brain and are emerging as promising targets in the management of neuropsychiatric disorders.

Maplight Therapeutics Inc.’s pricing of a $258.9 million financing this week revived the debate over whether targeting the M1 as well as the M4 muscarinic receptor – as Bristol Myers Squibb Co. does ...

Neumora Therapeutics, Inc. has announced the initiation of a Phase 1 study for NMRA-861, a potent and selective positive allosteric modulator of the M4 muscarinic receptor, aimed at treating ...

Addex spin-out Neurosterix begins phase 1 study with M4 PAM - NTX-253 for schizophrenia: Geneva, Switzerland Thursday, January 8, 2026, 12:00 Hrs [IST] Addex Therapeutics, a clini ...

In November, the Boston-based biotech firm Karuna Therapeutics submitted its new schizophrenia medication, called KarXT, to the US Food and Drug Administration for approval. If the agency gives KarXT ...

AbbVie's acquisition of Cerevel Therapeutics enhances its neuroscience pipeline with promising candidates Emraclidine and Tavapadon, expected to significantly boost revenues post-approval. Emraclidine ...

The EMERGENT-3 trial, published in the Journal of the American Medical Association Psychiatry, represents a significant advancement in the treatment of schizophrenia, particularly for individuals ...

Shenzhen Newrosetta Biosciences Co. Ltd. has divulged benzodiazepine derivatives acting as muscarinic M2 receptor antagonists reported to be useful for the treatment of myopia.

COBENFY represents the first new pharmacological approach to treat schizophrenia in decades, with a mechanism of action distinct from current therapies PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers ...